Actavis (ACT) to Acquire Forest Labs (FRX) in ~$25B Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- S&P, Nasdaq muted as bond yields rise; UnitedHealth boosts Dow
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- BofA profit hurt by provisions even as it expects rising interest income
- Morgan Stanley (MS) earnings beat lifts stock
- Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
SunTrust Downgrades Forest Laboratories (FRX) to Neutral
February 20, 2014 9:00 AM ESTSunTrust Robinson Humphrey downgraded Forest Laboratories (NYSE: FRX) from Buy to Neutral.
For an analyst ratings summary and ratings history on Forest Laboratories click here. For more ratings news on Forest Laboratories click here.
Shares of Forest Laboratories closed at $93.98 yesterday, with a 52 week range of $35.22-$70.86.... More
Developing Trend in M&A Suggests More Deals
February 19, 2014 3:54 PM ESTThere's a developing trend in M&A that has market watchers suggesting it could lead to an uptick in deals.
Yesterday, Actavis (NYSE: ACT) announced a $25 billion deal to acquire Forest Labs (NYSE: FRX). The deal was... More
Buckingham Research Downgrades Forest Laboratories (FRX) to Neutral
February 19, 2014 8:57 AM ESTBuckingham Research downgraded Forest Laboratories (NYSE: FRX) from Buy to Neutral.
For an analyst ratings summary and ratings history on Forest Laboratories click here. For more ratings news on Forest Laboratories click here.
Shares of Forest Laboratories closed at $91.04 yesterday, with a 52 week range of $35.22-$70.86.... More
Mizuho Securities Downgrades Forest Laboratories (FRX) to Neutral
February 19, 2014 8:55 AM ESTMizuho Securities downgraded Forest Laboratories (NYSE: FRX) from Buy to Neutral.
For an analyst ratings summary and ratings history on Forest Laboratories click here. For more ratings news on Forest Laboratories click here.
Shares of Forest Laboratories closed at $91.04 yesterday, with a 52 week range of $35.22-$70.86.... More
Goldman Sachs Downgrades Forest Laboratories (FRX) to Neutral
February 19, 2014 8:54 AM ESTGoldman Sachs downgraded Forest Laboratories (NYSE: FRX) from Buy to Neutral.
Analyst Jami Rubin said, "We believe ACT's announced acquisition of FRX has the potential to achieve synergies that should unlock substantial value for both FRX and ACT shareholders. We have long believed that... More
Goldman Sachs Upgrades Actavis (ACT) to Buy on Forest Labs Deal
February 19, 2014 6:42 AM ESTGoldman Sachs upgraded Actavis (NYSE: ACT) from Neutral to Buy with a price target of $250.00 (from $185.00). Analyst Jami Rubin thinks the planned acquisition of Forest Laboratories (NYSE: FRX) will help it become a full-fledged large cap pharma... More
Cantor Fitzgerald Downgrades Forest Laboratories (FRX) to Hold (IRWD)
February 18, 2014 11:55 AM ESTCantor Fitzgerald downgraded Forest Laboratories (NYSE: FRX) from Buy to Hold with a price target of $90.00. Analyst Irina Rivkind thinks a deal with Activist (NYSE: ACT) is likely.
"Due to the minimal overlap between Actavis and Forest products, we do not anticipate anti-trust issues to complicate the transaction. There are also no "deal-breaker" catalysts in Forest's near-term future that could derail the deal, in our view," said Rivkind. "Given Forest's attractiveness (young... More
Teva Pharmaceutical (TEVA) Gains on Sector Deal
February 18, 2014 9:53 AM ESTIn addition to gains this morning in Mylan, Inc. (NASDAQ: MYL) (+4.8%) and Allergan (NYSE: AGN) (+1.7%), Teva Pharmaceutical (NASDAQ: TEVA) (+3.1%) is seeing upside amid Actavis' (NYSE: ACT) deal to acquire Forest Laboratories, Inc. (NYSE: FRX) for ~$25 billion.... More
Traders Eye Next Pharma Deal After Actavis/Forest Labs Merger
February 18, 2014 7:59 AM ESTMylan, Inc. (NASDAQ: MYL) is on watch amid Actavis' (NYSE: ACT) deal to acquire Forest Laboratories, Inc. (NYSE: FRX) for ~$25 billion.
Also, while a much larger company, Allergan (NYSE: AGN) could be on watch as well.... More
Forest Laboratories (FRX) In Talks to Be Acquired by Actavis (ACT) for $25 Billion
February 17, 2014 11:09 PM ESTActavis plc (NYSE: ACT) is in advance talks to acquire Forest Laboratories, Inc. (NYSE: FRX) in a deal that could be worth up to $25 billion, according to sources cited by the Wall Street Journal late Monday.
... More
